Home / Oncology (page 144)

Oncology

Roche’s Ventana Enters Deal to Develop Companion Diagnostic Test for Astellas Cancer Compound

Roche’s Ventana Medical Systems has inked a deal with Astellas Pharma aimed at developing new diagnostic tests for targeted cancer treatments. The cancer diagnostics company announced that it has entered into master collaboration agreement with Astellas Pharma to develop novel automated tissue diagnostics in support of therapeutic compounds in development. …

Read More »

Specialty Drugs Drove Significant Increase in US Drug Spending in 2014

Driven by innovative, yet expensive new specialty drugs, US spending on prescription drugs jumped 13 percent to $374 billion in 2014, the largest percentage increase since 2001, according to a new report. The significant increase was primarily due to the introduction of expensive breakthrough drugs, manufacturer price hikes and a …

Read More »

Medivir and Cancer Research Technology Team Up to Develop A New Class of Cancer Drugs

Swedish biotech Medivir and Cancer Research Technology (CRT) are teaming up to develop a new class of drugs that have shown promise in various cancer types. Medivir and CRT, Cancer Research UK’s commercialization and development arm, said that they have partnered to develop a new class of drugs targeting ADAM8, …

Read More »

Roche Acquires Genomics Research Company CAPP Medical

Roche has acquired a Stanford University-founded genomics research company, CAPP Medical, in an effort to strengthen its oncology translational research pipeline. The company announced today that it has acquired CAPP Medical to advance the development of technology for cancer screening and monitoring through the detection of circulating tumor DNA (ctDNA) …

Read More »

New Drug for Rare Lymphoma Demonstrates Sustained Benefit at Two Years

New data shows that Pharmacyclics and partner Janssen’s Imbruvica (ibrutinib) provides ongoing control of Waldenstrom’s macroglobulinemia (WM). Investigators from Dana-Farber Cancer Institute reported that the most recent results from a clinical trial show that ibrutinib continued to control the rare blood cancer, with 95 percent of patients surviving for two …

Read More »

FDA Grants Fast Track Status to Exelixis’ Kidney Cancer Drug

The US Food and Drug Administration (FDA) has granted Fast Track designation to Exelixis’ renal cell carcinoma (RCC) drug. The agency provided fast track status for Exelixis’ investigational cabozantinib for the treatment of patients with advanced RCC who have received one prior therapy. The news sent the company’s shares up …

Read More »

Research Initiative Aims to Uncover First Biomarker for Pancreatic Cancer

Small Boston-based biotech, Berg Pharma, is collaborating with hospitals and research teams to discover and validate the first-ever clinical biomarker to diagnose and treat pancreatic cancer. The cross-sector collaboration includes Berg, a biopharmaceutical company committed to uncovering health solutions through a data driven, biological research approach; the Cancer Center at …

Read More »

Clovis Oncology’s Ovarian Cancer Candidate Wins Breakthrough Status from the FDA

Colorado-based Clovis Oncology, Inc. announced that US health regulators granted Breakthrough Therapy designation to its ovarian cancer candidate, sending shares up nearly nine percent in after-hours Monday. The company said that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to its investigational PARP inhibitor, rucaparib, as …

Read More »